The FDA will convene an adcomm in September to weigh approval of Grail's Galleri cancer test, which missed the primary endpoint of a 142,000-person UK trial.
Endpoints News
@endpts
The biopharma world is here. Get the industry’s most comprehensive daily news reports at endpts.com/subscribe
- A bipartisan pair of senators introduced BINSA, reviving a divisive bill that would have Treasury screen US investments and licensing deals in China biotech.
- "What I think will slow it down is what actually happens in China itself," Pfizer's Andrew Baum said at Endpoints' China biotech debate in Cambridge on Thursday, predicting the surge will cool as Chinese companies take on riskier first-in-class science.
- In this week's Peer Review: J&J's Jennifer Taubert retires after eight years leading Innovative Medicine, BioNTech taps Sobi's Guido Oelkers as its next CEO, and ReCode names Heather Clark chief executive.
- BlossomHill and Latigo raised a combined $496M, capping biotech's busiest IPO week in years.
